KR20070029254A - Hpv 16과 hpv 18 및 적어도 hpv 31, 45 또는52로부터 선택된 또 다른 hpv 유형에 대한 백신 - Google Patents

Hpv 16과 hpv 18 및 적어도 hpv 31, 45 또는52로부터 선택된 또 다른 hpv 유형에 대한 백신 Download PDF

Info

Publication number
KR20070029254A
KR20070029254A KR1020077001065A KR20077001065A KR20070029254A KR 20070029254 A KR20070029254 A KR 20070029254A KR 1020077001065 A KR1020077001065 A KR 1020077001065A KR 20077001065 A KR20077001065 A KR 20077001065A KR 20070029254 A KR20070029254 A KR 20070029254A
Authority
KR
South Korea
Prior art keywords
hpv
vlps
vlp
composition
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077001065A
Other languages
English (en)
Korean (ko)
Inventor
세르게 데브루스
마리-테레세 마틴
로버트 존 스티븐
진 스테펜느
마틴 안네 쎄실 웨텐도르프
Original Assignee
글락소스미스클라인 바이오로지칼즈 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0413510.9A external-priority patent/GB0413510D0/en
Priority claimed from US11/114,301 external-priority patent/US20050287161A1/en
Application filed by 글락소스미스클라인 바이오로지칼즈 에스.에이. filed Critical 글락소스미스클라인 바이오로지칼즈 에스.에이.
Publication of KR20070029254A publication Critical patent/KR20070029254A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020077001065A 2004-06-16 2005-06-14 Hpv 16과 hpv 18 및 적어도 hpv 31, 45 또는52로부터 선택된 또 다른 hpv 유형에 대한 백신 Ceased KR20070029254A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0413510.9A GB0413510D0 (en) 2004-06-16 2004-06-16 Vaccine
GB0413510.9 2004-06-16
US11/114,301 US20050287161A1 (en) 2002-12-20 2005-04-26 Vaccine
US11/114,301 2005-04-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020127027786A Division KR101359943B1 (ko) 2004-06-16 2005-06-14 Hpv 16과 hpv 18 및 적어도 hpv 31, 45 또는 52로부터 선택된 또 다른 hpv 유형에 대한 백신

Publications (1)

Publication Number Publication Date
KR20070029254A true KR20070029254A (ko) 2007-03-13

Family

ID=35160037

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077001065A Ceased KR20070029254A (ko) 2004-06-16 2005-06-14 Hpv 16과 hpv 18 및 적어도 hpv 31, 45 또는52로부터 선택된 또 다른 hpv 유형에 대한 백신

Country Status (18)

Country Link
EP (1) EP1758609B1 (cg-RX-API-DMAC7.html)
JP (1) JP2008502633A (cg-RX-API-DMAC7.html)
KR (1) KR20070029254A (cg-RX-API-DMAC7.html)
AR (1) AR049354A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005253723B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0512042B8 (cg-RX-API-DMAC7.html)
CA (1) CA2566620C (cg-RX-API-DMAC7.html)
FR (2) FR15C0082I2 (cg-RX-API-DMAC7.html)
IL (1) IL179138A0 (cg-RX-API-DMAC7.html)
LU (3) LU92899I2 (cg-RX-API-DMAC7.html)
MA (1) MA28692B1 (cg-RX-API-DMAC7.html)
MX (1) MXPA06014515A (cg-RX-API-DMAC7.html)
NO (1) NO20070195L (cg-RX-API-DMAC7.html)
PE (1) PE20060434A1 (cg-RX-API-DMAC7.html)
PL (1) PL1758609T3 (cg-RX-API-DMAC7.html)
RU (1) RU2420313C2 (cg-RX-API-DMAC7.html)
SG (1) SG153837A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005123125A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130083426A (ko) * 2009-06-19 2013-07-22 아이진 주식회사 자궁경부암 백신

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007013475A (es) * 2005-04-26 2008-04-02 Glaxosmithkline Biolog Sa Vacuna.
ES2519490T3 (es) * 2008-07-31 2014-11-07 Glaxosmithkline Biologicals S.A. Vacuna contra HPV
CN103119168A (zh) * 2010-07-15 2013-05-22 不列颠哥伦比亚癌症局分支机构 人乳头瘤病毒e7抗原组合物及其用途
EP3269388A1 (en) 2012-10-30 2018-01-17 Pfizer Inc. Recombinant particle based vaccines against human cytomegalovirus infection
CA2965498A1 (en) * 2014-10-24 2016-04-28 Hpvvax, Llc. Compositions and uses of a papilloma virus (hpv) vaccine for the treatment of hpv related cancer and skin lesions
CN107188966B (zh) 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
PT1572233E (pt) * 2002-12-20 2011-06-07 Glaxosmithkline Biolog Sa Utilização de hpv16 e hpv18 como vacina contra um ou mais de tipos de hpv oncogénicos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130083426A (ko) * 2009-06-19 2013-07-22 아이진 주식회사 자궁경부암 백신

Also Published As

Publication number Publication date
RU2006143804A (ru) 2008-08-20
LU92899I2 (fr) 2016-03-08
AR049354A1 (es) 2006-07-19
CA2566620A1 (en) 2005-12-29
WO2005123125A1 (en) 2005-12-29
CA2566620C (en) 2014-03-11
MXPA06014515A (es) 2007-03-23
FR15C0082I2 (fr) 2016-10-28
EP1758609A1 (en) 2007-03-07
AU2005253723B2 (en) 2011-01-20
LU92900I2 (fr) 2016-03-08
BRPI0512042A (pt) 2008-02-06
PE20060434A1 (es) 2006-06-08
AU2005253723A1 (en) 2005-12-29
JP2008502633A (ja) 2008-01-31
BRPI0512042B1 (pt) 2019-01-22
LU92898I2 (fr) 2016-03-08
RU2420313C2 (ru) 2011-06-10
IL179138A0 (en) 2007-03-08
FR15C0082I1 (fr) 2016-01-08
EP1758609B1 (en) 2012-10-03
PL1758609T3 (pl) 2013-02-28
FR15C0084I1 (cg-RX-API-DMAC7.html) 2016-01-08
SG153837A1 (en) 2009-07-29
FR15C0084I2 (fr) 2016-10-28
NO20070195L (no) 2007-01-15
MA28692B1 (fr) 2007-06-01
BRPI0512042B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
US20050287161A1 (en) Vaccine
JP2012102132A (ja) Hpv16およびhpv18ならびにhpv31、45または52から選ばれる少なくとも1つの別のhpv型に対するワクチン
EP1758609B1 (en) Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
US20090181052A1 (en) Vaccine
US7758866B2 (en) Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
US7858098B2 (en) Vaccine
CN100418577C (zh) Hpv-16和hpv-18l1vlp疫苗
CN101217976A (zh) 疫苗
KR20080005583A (ko) 백신
CN101217975A (zh) 疫苗
BRPI0610396A2 (pt) vacina de hpv multivalente, métodos para proteger um paciente contra a infecção, para prevenir ou reduzir a freqüênca de anormalidades citológicas em um paciente, para prevenir a formação de lesões cin histologicamente confirmadas e para fabricar a vacina, e, usos de uma composição, de uma vacina e de uma composição de vacina
BRPI0610032A2 (pt) uso de uma proteìna l1 do papilomavìrus humano ou fragmento imunogêico da mesma de um primeiro tipo de hpv, programa de vacinação para proteção contra a infecção e/ou doença por hiv, método para prevenção da infecção e/ou doença por hpv, composição de vacina, e, kit
HK1085378B (en) Use of hpv16 and hpv18 as vaccine against one or more of oncogenic hpv type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070116

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20100527

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120224

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20120713

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20120224

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20121012

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20121015

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20120713

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2012101008848

Request date: 20121015

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20121024

J501 Disposition of invalidation of trial
PJ0501 Disposition of invalidation of trial

Appeal kind category: Appeal against decision to decline refusal

Request date: 20121015

Appeal identifier: 2012101008848